Treatment Advancements in Newly Diagnosed and Relapsed/Refractory in Multiple Myeloma - Episode 12
Panelists discuss how subgroup analyses of cilta-cel support its efficacy in high-risk cytogenetics and extramedullary disease, though bridging therapy and patient selection remain key for optimal outcomes.
Subgroup Analysis of Cilta-cel in High-Risk Myeloma
Subgroup data from the CARTITUDE-4 study confirm that cilta-cel remains effective in patients with high-risk cytogenetics and extramedullary disease. While these groups typically have poor outcomes, cilta-cel provided notable improvements in progression-free survival.
However, extramedullary disease continues to present challenges, with responses being less durable than in bone-only disease. The need for further innovation in this subgroup remains critical, even as outcomes improve with CAR T therapy.
Clinicians are encouraged to initiate disease control with bridging regimens before CAR T infusion to optimize safety and efficacy. Early referral and preparation are essential for ensuring access and reducing attrition before CAR T administration.